A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts. Int J Infect Dis.
Fay FF, Alvarez-Moreno CA, Bonvehi PE, Espinoza CC, Hidalgo MLH, Marcano-Lozada M, Perez CM, Pulchinelli A Jr, Sáenz-Flor KV, Condino- Neto A. 20/05/2021
Abstract Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection by COVID-19 in 5 Colombian institutions. Conclusions: The clinical course of SARS-CoV-2 infection in hospitalized Colombian was characterised by a more advanced stage of the infection.
Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia
Yomayusa-Gonzalez N., Chacón-Acevedo, K.R., Ávila-Reina, AJ., ...Combariza-Vallejo, J.F., Álvarez-Moreno, C. 19/07/2021
Abstract Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection by COVID-19 in 5 Colombian institutions.
Conclusions: The clinical course of SARS-CoV-2 infection in hospitalized Colombian was characterised by a more advanced stage of the infection.
Associated Factors for Mortality in a COVID-19 Colombian Cohort by Epidemic Wave: Is the Predominance of Mu Variant Relevant? Lancet. 12
Alvarez-Moreno C, De La Hoz Siegler I, Rojas J, Bravo Ojeda J, Chacón J, Yomayusa N, Patiño S, Gomez-Nieto K, Martínez Pinzón V, Toloza C, Tarud Ayub R, Rengifo P. 12/12/2022
Background
The third epidemic wave reported the greatest number of deaths related to SARS-CoV-2 in Colombia. In this wave, the Mu variant was predominant in 75% of the cases. Therefore, we evaluated the association between Colombia's third wave and COVID-19 all-cause inhospital mortality.
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet.
WHO Solidarity Trial Consortium. 02/05/2022
Background
The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued for futility but randomisation to remdesivir continued. Here, we report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date.